Patent ID: 11944644
Assignee: THE MEDICAL RESEARCH, INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 7:
8. The T-cell of claim 7, comprising either at least one copy of a DNA construct selected from the group consisting of:
(I) a DNA construct encoding for: (A) from 5′ to 3′, (i) a leader peptide, (ii) anti-CD138 scFv, (iii) a transmembrane domain I, (iv) a costimulatory domain or an activation domain, and (B) from 5′ to 3′ (v) a leader peptide, (vi) anti-CD38 scFv domain, (vii) a transmembrane domain II and (viii) an activation domain or a costimulatory domain; wherein (A) and (B) are separated by a self-cleaving peptide;
(II) a DNA construct encoding, from 5′ to 3′, (i) a leader peptide, (ii) anti-CD138 scFv, (iii) a transmembrane domain I, (iv) a costimulatory domain, (v) a self-cleaving peptide, (vi) a leader peptide, (vii) anti-CD38 scFv domain, (viii) a transmembrane domain II and (ix) an activation domain; and
(III) a DNA construct encoding from 5′ to 3′, (i) a leader peptide, (ii) anti-CD38 scFv, (iii) a transmembrane domain II, (iv) an activation domain, (v) a self-cleaving peptide, (vi) a leader peptide, (vii) anti-CD138 scFv domain, (viii) a transmembrane domain I and (ix) a costimulatory domain, or two different DNA constructs, wherein the first DNA construct comprises a DNA sequence encoding, from 5′ to 3′, (i) a leader peptide, (ii) anti-CD138 scFv, (iii) a transmembrane domain I and (iv) a costimulatory domain or an activation domain, and the second DNA construct comprises a DNA sequence encoding from 5′ to 3′ (i) a leader peptide, (ii) anti-CD38 scFv domain, (iii) a transmembrane domain II and (iv) an activation domain or a costimulatory domain.